Quqiu Zhili Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is released as two process models under the manufacturer’s technical file: QZ-V-0284 (fine powder) and QZ-V-0284-C (compacted granules). The fine-powder model is controlled to a laser-diffraction D90 ≤ 150 µm; the compacted model is densified to a D50 range of 180–425 µm. The substance is manufactured and released under veterinary active pharmaceutical ingredient GMP principles rather than feed-additive quality. The specified quality framework covers identity, assay by HPLC against a declared marker, related substances, loss on drying, total ash, bulk density, particle size distribution, bioburden, and residual solvents. The two-model system exists because the same API cannot be optimised simultaneously for dust-free premix blending and for rapid dissolution in sterile injectable manufacturing. Table 2 summarises the model selection logic.

On production packaging lines, the fine-powder model generates dust during vibratory sieving and open transfer; local dust extraction is required, and exposure above 60% RH is controlled to avoid hygroscopic bridging. The compacted model reduces fugitive dust and improves automatic bulk filling accuracy. Batch-to-batch variance in bulk density is controlled by USP<616>; lots outside 0.35–0.55 g/mL are routed away from direct compression or capsule filling and are evaluated for wet granulation or solution manufacture. This physical specification is a practical difference from feed-grade products that may not control bulk density or bioburden.

Packaging selection follows the sorption profile of the API. The fine powder is filled into double polyethylene liners inside fibre drums; desiccant is added for shipments that cross humid zones. Both models are stored at ≤ 25 °C in the unopened original container. Material held above 30 °C for more than 30 days should be re-tested for marker assay and moisture unless the stability programme has qualified a wider excursion. The compacted model tolerates vibration during transport better than the fine powder due to reduced particle fracture.

Why Is the Veterinary API Grade Not Interchangeable with Feed-Additive or Technical Powder?

The distinction is not limited to marker assay. Feed-additive material may be accepted on assay and simple heavy-metal limits, but the veterinary API grade must be evaluated for residual solvents under VICH GL18, elemental impurities under USP<232>, and microbial quality under USP<61>/USP<62>. A technical-grade lot with a similar HPLC assay can still fail pharmaceutical use because of a residual solvent above the permitted daily exposure or because of a coarse tail above the dissolution-relevant D90. For injectable products, bioburden and endotoxin are imposed at the finished-product level; the raw API is only one input into that control strategy. Table 1 documents the manufacturer’s registered release criteria for model QZ-V-0284.

Because the marker profile of botanical-derived veterinary APIs can vary with harvest season, extraction lot, and post-extraction storage, the manufacturer uses a chromatographic fingerprint in addition to a single-marker assay. HPLC-UV profiles are compared against a reference chromatogram across 210–400 nm; any new peak above 0.5% triggers a related-substances investigation. This requirement is a material difference from synthetic APIs whose impurity profile is defined by the synthetic route. Release of Quqiu Zhili Powder Veterinary Grade API therefore depends on a chromatographic similarity threshold as well as quantitative marker assay.

Processing Windows for Tablet and Capsule Granulation with Quqiu Zhili Powder

Wet granulation is the more common route for tablets and capsules because the cohesive characteristics of the fine-powder model can interfere with direct compression. In high-shear granulation, the milled API is dry-blended with microcrystalline cellulose, pregelatinised starch, and crospovidone. A binder solution of povidone in water is metered into a high-shear mixer with an impeller tip speed of 3–6 m/s and a chopper speed of 1000–1500 rpm; final wet-mass formation is judged by impeller torque rather than by fixed time. The wet granules are transferred to a fluid-bed dryer with inlet air temperature originally set at 55–65 °C, but this limit must be confirmed by forced-degradation data because published data for this specific botanical configuration is limited.

Dried granules are milled through a 0.8–1.2 mm screen and lubricated with magnesium stearate before compression. A practical target for loss on drying after granulation is ≤ 2.5%; granule moisture above 3.0% increases sticking and picking on tablet punches. Tablet compression trials on a rotary press with 9 mm round tooling require a compression force of 8–14 kN and pre-compression force of 1.5–3.0 kN to keep friability below 1.0% when measured by USP<1216>. Hardness in the range 50–80 N has been used to balance disintegration and mechanical strength, but the registered formulation must be optimised for the target species because tablet hardness alone does not guarantee bioavailability in ruminant or monogastric dosing.

Capsule filling from the fine-powder model is performed after dry granulation or slugging. When QZ-V-0284-C compacted granules are used, dosator-type capsule machines can fill the product with less dust generation. A glidant such as colloidal silicon dioxide at 0.5–1.0% and a lubricant blend time not exceeding 5 min in a diffusion mixer are typical to prevent flow loss from over-lubrication.

Thermal and Moisture Stability Limits Observed in Premix and Oral Granule Production

For premixes, QZ-V-0284-C is preferably diluted onto a carrier such as ground maize cob, rice hulls, or lactose monohydrate because the compacted granules reduce fugitive dust and improve blend uniformity. Blending is performed at ≤ 60% RH; exposure above 60% RH can lead to hygroscopic bridging and caking on the walls of ribbon or paddle blenders. The API is not classified as highly hygroscopic, but moisture uptake above 5.0% has been observed on open handling lines in high-humidity regions. If the premix is incorporated into pelleted feed, the conditioner temperature and die retention time must be considered. Feed-conditioning temperatures above 75 °C require product-specific thermal stability data; published data for this specific configuration is limited, and a process-validation batch should be conducted before commercial scale-up. Steam conditioning should be kept as short as possible, and the API-bearing premix should not be re-pelleted unless the manufacturer has demonstrated marker assay stability.

When Direct Compression Is Evaluated in Place of Wet Granulation

Direct compression is limited to formulations containing QZ-V-0284-C and high proportions of free-flowing excipients. The fine-powder model QZ-V-0284 is normally not used because its flow character and bulk density variability create segregation and weight-control errors. When direct compression is evaluated, a V-blender or bin blender is operated at 10–15 rpm, and magnesium stearate is added to a final blend step not exceeding 5 min; over-lubrication is a common cause of tablet capping on production presses. Colloidal silicon dioxide at 0.5–1.0% can be included to improve flow. Tablet hardness for direct-compressed veterinary formulations is often lower than for wet-granulated product, in the range 40–70 N, with disintegration time not exceeding 15 min in 0.1 N HCl at 37 °C when tested by the compendial disintegration method. The route is acceptable only when hardness and disintegration remain within the registered specification for the target species.

Injectable Processing Demands

Injectable manufacture requires dissolution, clarification, sterilising filtration, and aseptic filling. The fine-powder model QZ-V-0284 is preferred because the controlled D90 ≤ 150 µm supports dispersion in water for injection at 20–25 °C. The bulk solution is prepared by adding the API to a portion of water for injection under low-speed stirring; high-shear rotor-stator mixing is avoided unless solubility and stability data show that it is necessary because air incorporation can increase oxidative stress. The solution pH is adjusted into the range defined by the finished product stability protocol, and tonicity is adjusted to 280–320 mOsm/kg if an isotonic injection is required. The solution is passed through a 0.45 µm clarifying filter and a 0.22 µm sterilising-grade membrane. Filter integrity is tested before and after use per USP<71> and applicable GMP annexes. Terminal sterilisation at 121 °C for 15 min may be considered only if forced-degradation studies demonstrate no loss of marker assay below the registered limit; published data for this specific configuration is limited, and therefore aseptic filtration remains the default process for heat-sensitive veterinary APIs of botanical origin.

Endotoxin control is not a fixed raw-material limit for all dosage forms. The raw API can be released with a bioburden limit, and the finished injection must meet the calculated endotoxin limit for the maximum intended dose and target species body weight under USP<85> or EP 2.6.14. A batch can fail at the finished-product level even if the API passes a general endotoxin screen.

Oral powders and drinking-water solutions for poultry or swine are prepared by dry filling the fine-powder model into sachets, bulk jars, or water-soluble dosing systems. The powder is added to drinking water with continuous low-shear mixing; high-shear rotor-stator devices are avoided because air incorporation can reduce chemical stability and create foam. The prepared solution is used within 24 h when no preservative is present and stored below 25 °C; if a preserved system is used, the preservative effectiveness must be confirmed by USP<51>. The compacted model is not preferred for drinking-water solutions because the larger granule size requires longer dispersion time; if QZ-V-0284-C is the only available model, deagglomeration through a 0.5 mm screen is recommended before addition to the water tank.